Table 1.
Baseline demographic and clinical characteristics.
| Recurrence group | control group | |
|---|---|---|
| Age group | ||
| >35 | 51 (85%) | 51 (85%) |
| ≤35 | 9 (15%) | 9 (15%) |
| Clinical stage | ||
| I | 1 (1.67%) | 1 (1.67%) |
| IIA | 7 (11.67%) | 9 (15.00%) |
| IIB | 19 (31.67%) | 22 (36.67%) |
| IIIA | 15 (25.00%) | 13 (21.67%) |
| IIIB | 14 (23.33%) | 15 (25.00%) |
| IIIC | 2 (3.33%) | 0 |
| IV | 1 (1.67%) | 0 |
| Unknown | 1 (1.67%) | 0 |
| Skin involvement | ||
| Yes | 14 (23.33%) | 14 (23.33%) |
| No | 46 (76.67%) | 46 (76.67%) |
| Clinical lymph node status | ||
| N0 | 13 (21.67%) | 13 (21.67%) |
| N1 | 33 (55.00%) | 33 (55.00%) |
| N2 | 14 (23.33%) | 14 (23.33%) |
| Clinical tumor size (cm) | ||
| 1 | 1 (1.67%) | 3 (5.00%) |
| 2 | 9 (15.00%) | 4 (6.67%) |
| 3 | 12 (20.00%) | 16 (26.67%) |
| 4 | 6 (10.00%) | 11 (18.33%) |
| 5 | 7 (11.67%) | 9 (15.00%) |
| 6 | 9 (15.00%) | 9 (15.00%) |
| 7 | 5 (8.33%) | 3 (5.00%) |
| 8 | 2 (3.33%) | 2 (3.33%) |
| 9 | 1 (1.67%) | 1 (1.67%) |
| 10 | 2 (3.33%) | 1 (1.67%) |
| 11 | 5 (8.33%) | 0 |
| Unknown | 1 (1.67%) | 1 (1.67%) |
| Histological type | ||
| Ductal | 51 (85%) | 54 (90.00%) |
| Lobular | 2 (3.33%) | 3 (5.00%) |
| Ductal-lobular | 6 (10.00%) | 2 (3.33%) |
| Other | 1 (1.67%) | 1 (1.67%) |
| Histological grade | ||
| Grade I | 1 (1.67%) | 2 (3.33%) |
| Grade II | 21 (35.00%) | 19 (31.67%) |
| Grade III | 29 (48.33%) | 27 (45.00%) |
| Unknown | 9 (15.00%) | 12 (20%) |
| Lymphovascular involvement | ||
| Yes | 26 (43.33%) | 13 (21.67%) |
| No | 34 (34%) | 47 (78.33%) |
| Estrogen receptor status | ||
| <20 | 29 (48.33%) | 27 (45.00%) |
| 20–49 | 8 (13.33%) | 11 (18.33%) |
| 50–100 | 10 (16.67%) | 6 (10.00%) |
| >100 | 6 (10.00%) | 8 (13.33%) |
| Unknown | 7 (11.67%) | 8 (13.33%) |
| Progesterone receptor status | ||
| <5 | 26 (43.33%) | 27 (45.00%) |
| 5–30 | 5 (8.33%) | 10 (16.67%) |
| 31–50 | 2 (3.33%) | 1 (1.67%) |
| 51–100 | 12 (20%) | 4 (6.67%) |
| >100 | 7 (11.67%) | 9 (15.00%) |
| Unknown | 8 (13.33%) | 9 (15.00%) |
| Positive ER PR status | 29 (54.7%) | 31 (59.6%) |
| Negative ER PR status | 24 (45.2%) | 21 (40.3%) |
| Unknown | 7 | 8 |
| HER2/NEU expression | ||
| Negative | 32 (76.19%) | 27 (81.81%) |
| Positive | 10 (23.81%) | 6 (19.19%) |
| Unknown | 18 | 27 |
| Extracapsular involvement | ||
| No | 52 (86.67%) | 53 (88.33%) |
| Yes | 8 (13.33%) | 7 (11.67%) |